SEARCH · PubMed Health
Results for “DOSAGE FORMS”
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Transdermal delivery system--a unique drug dosage form.
Explore the source record for details and available documents.
Drug dosage forms: part one.
Explore the source record for details and available documents.
Development of a novel dosage form for intramuscular injection of titrated extract of Centella asiatica in a mixed micellar system.
Titrated extract of Centella asiatica (TECA), a drug used in treating systemic scleroderma, is poorly water-soluble. A conventional dosage form for the intramuscular injection of TECA, propylene glycol (PG)-based TECA solution, causes severe pain after intramuscular injection. To improve the solubility of TECA and reduce pain after injection, mixed micellar systems composed of 10% surfactant mixture (Tween 20 and Tween 85) and 90% phosphate-buffered saline, pH 7.0 (PBS) were prepared. As the ratio of Tween 20 to Tween 85 increased from 0:10 to 10:0, the solubility of TECA in the mixed micellar systems increased from 7- to 26-fold compared to that in PBS (pH 7.0). The droplet size of micelles gradually decreased with the increasing ratio of Tween 20 to Tween 85 from 0:10 to 4:6, followed by an abrupt decrease in size above the ratio of 6:4. Furthermore, the micellar systems prepared with Tween 20 and Tween 85 at the ratio of 6:4, 8:2 or 10:0 could solubilize TECA more than 10 mg/ml and the resultant droplet sizes were less than 2 microm. No significant changes were observed in the droplet sizes and asiaticoside contents in these micellar formulations during storage, indicating these systems are stable for at least 60 days. Their osmotic pressures were remarkably lower than those of PG-based TECA solution and similar to that of saline solution, irrespective of dilution ratios. Most importantly, they markedly reduced the number of writhes compared with PG-based TECA solution after injection to mice. All of these results suggest that these three TECA micellar formulations prepared with Tween 20 and Tween 85 improved the solubility of TECA and reduced pain following injection, possibly due to the decrease in osmotic pressure. Thus, these micellar formulations composed of optimum ratios of Tween 20 and Tween 85 may have a potential as dosage forms for the intramuscular injection of a poorly water-soluble TECA.
High-performance liquid chromatographic determination of selected flavonols in Ginkgo biloba solid oral dosage forms.
PURPOSE: This paper describes a validated high-performance liquid chromatographic (HPLC) - photodiode array (PDA) detection method to quantitate five flavonol components as markers; rutin, quercitrin, quercetin, kaempferol and isorhamnetin for use in the quality control of Ginkgo biloba dosage forms. METHODS: Separation was achieved using a minibore Phenomenex Luna 5microm C(18) (2) column with dimensions 250 x 2.00mm at 45 degrees C with a one step linear gradient using acetonitrile:formic acid (0.3%) at a flow rate of 0.4ml/min. RESULTS: The limits of quantitation for the flavonols were 2.76, 0.77, 1.11, 1.55 and 1.03microg/ml for rutin, quercitrin, quercetin, kaempferol and isorhamnetin, respectively. This method is linear over concentration ranges of 3-26microg/ml for all flavonols. Recoveries for rutin, quercitrin and kaempferol were above 94% while quercetin and isorhamnetin had average recoveries of 83% and 76%, respectively. Intraday precision did not exceed 6% and with-in day precision was better than 12% for all compounds. CONCLUSION: A suitable method was developed to identify and quantitate five relevant flavonol marker compounds and was successfully used to assay some commercially available solid oral dosage forms of Ginkgo biloba .
Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasted and fed conditions in humans.
PURPOSE: This study was undertaken to examine the effects of mechanical destructive forces on drug release from controlled release (CR) dosage forms in vitro and in vivo and their colonic release, using two CR tablets of acetaminophen A and B, showing slower and faster erosion rates, respectively. METHODS: In vitro release rates were determined by several official methods. Tablets were administered to healthy volunteers under fasting and fed conditions. RESULTS: Both tablets showed similar release rates under mild destructive conditions (e.g., paddle method at 10 rpm) but CR-B showed faster release under highly destructive conditions (e.g., rotating basket method at 150 rpm), where the tablet was eroded. The in vivo release from CR-B was faster than from CR-A, possibly because of enhanced erosion. The variable in vivo release from CR-B indicated large inter-subject differences in destructive GI forces. The fastest in vivo release from CR-B among individuals was approximated by the in vitro dissolution determined by destructive methods such as the rotating basket at 150 rpm. The slowest in vivo release from tablets A and B was lower than the dissolution by the paddle method at 10 rpm. The release from both tablets was markedly reduced at 3-4 hrs after dosing irrespective of feeding conditions which can be attributed to release inhibition in the colon. CONCLUSIONS: Effects of GI destructive forces on the tablet erosion and the release inhibition in the colon must be considered in the development of CR dosage forms.
Reverse-phase liquid chromatographic determination of dexamethasone acetate and cortisone acetate in bulk drug substance and dosage forms: collaborative study.
A reverse-phase liquid chromatographic method for determination of dexamethasone acetate and of cortisone acetate was subjected to an interlaboratory study by 8 collaborators for each steroid acetate. Bulk drug substance, suspensions, and tablets were assayed. Bulk drug or dosage form is dissolved in an acetonitrile-buffer mixture and analyzed by an external standard method. The steroid acetate is resolved from extraneous components by reverse-phase chromatography and detected at 254 nm. The sample solutions are stable for at least 72 h. For dexamethasone acetate, coefficients of variation were 0.9 and less than or equal to 3.1% for the bulk drug substance and the suspensions, respectively. For cortisone acetate, coefficients of variation were 0.7% for bulk material, less than or equal to 2.0% for suspensions, and less than or equal to 2.5% for tablets. All dosage forms were commercial formulations. The 2 methods have been adopted official first action.
Prediction of in vivo drug release behavior of controlled-release multiple-unit dosage forms in dogs using a flow-through type dissolution test method.
A newly designed flow-through type dissolution test method (FT method) was applied to predict in vivo drug release behaviors in dogs of controlled-release multiple unit dosage forms. The in vivo drug release behaviors were directly observed by measuring the residual amount of drugs in preparations recovered from the gastrointestinal (GI) tract after oral administration. Theophylline (TP), acetaminophen (AA), and phenylpropanolamine hydrochloride (PPA), which have different solubility, were used as model drugs. In vivo drug release behaviors in the gastrointestinal (GI) tract of dogs were similar to the results of the Wagner-Nelson method. In vivo release behaviors of TP and AA, until 2h after administration, were well correlated to in vitro behaviors obtained by the paddle method at 100 rpm. However, the in vivo release rates of TP and AA were gradually decreased because of a lack of fluid in the lower region of the GI tract, their poor solubility, the difference of the release rates, and so on. Non-sink conditions, which would reflect TP and AA release in the lower region of the GI tract, were obtained by the FT method at a cell volume of 0.5 ml and a flow rate of 0.37 ml/h (TP), 0.48 ml/h (AA), respectively. The in vitro release profiles obtained by the FT method combining sink and non-sink conditions were similar to their in vivo profiles. On the other hand, in the case of PPA, the in vivo release profiles were considerably similar to the in vitro ones obtained by both the paddle method and the FT method. In conclusion, the FT method combining sink and non-sink conditions will give a good in vitro/in vivo correlation regarding release behavior for controlled-release multiple unit dosage forms.
[Novel dosage forms with a sustained release of aqueous cis-platinum].
The authors have been devising novel dosage forms with a sustained release of aqueous cis-platinum (CDDP), following the concept of a drug delivery system. First, we prepared biodegradable vehicles with clinically available fibrin and gelatin materials that were used with the ultraviolet (UV)-cross linking technique. Then, each carrier was loaded with CDDP to form new drugs. We basically studied degradability of the carrier, a release profile of the CDDP, and antineoplastic activities with the system. The new drugs gradually disintegrated to dissolve completely within 10-15 days, and 80-90% of the loaded CDDP was delivered in the same period. The released CDDP showed antineoplastic activities, both in vitro and in vivo, while the CDDP directly reacted with human plasma revealed little evidence of anticancer function. The scanning electron microscopic studies suggested that the release profile of the CDDP was closely related with the degradability of the carrier. We presume that UV-modification techniques play important roles in preparation of the new drug carriers. Our newly devised CDDP releasing system is promising as novel cancer chemotherapy.
Research and development of phamaceutical dosage forms.
The development of a suitable formulation and a freeze-dry cycle for a pharmaceutical dosage form requires knowledge of some basic properties such as (1) eutectic temperature, if one exists, (2) temperature effect on solubility, (3) degree of supercooling, (4) heat transfer properties of the frozen product and (5) equipment design and equipment capability. Basic work with several inorganic and organic salts shows that eutectic temperature is a function of the melting point and the differential heat of solution of a drug. From a knowledge of these parameters, a mathematical expression can be used to estimate eutectic temperature. The desired characteristics which can be achieved by proper formulation of the solution to be freeze-dried and by employing optimum freeze-drying cycles include an intact cake, sufficient strength, uniform color and rapid reconstitution. By utilizing resistivity measurements to determine eutectic temperature and supercooling properties it is possible to reformulate products, increase batch sizes and reduce overall times for freeze-drying cycles.
Effects of epidermal growth factor dosage forms on mice full-thickness skin wound zinc levels and relation to wound strength.
Epidermal growth factor (EGF) and zinc promote re-epithelization and reparative tissue strength by enhancing deposition of collagen at the site of the wound. In this study two EGF dosage forms were chosen to assess the effect of zinc levels on wound healing and for comparison with wound tear strengths. A solution of EGF in 0.9% w/v NaCl and an EGF gel in 0.2% Carbopol 940 polymer (5 microL) were applied to full-thickness skin wounds of mice twice a day for 7 and 15 days. Wound zinc levels were higher on day 7 than on day 15, especially in wounds treated with EGF. The wound zinc levels of the gel + EGF group on day 15 were similar to those of normal control skin. These results imply that there is a close connection, but no direct relationship, between EGF application in both dosage forms and wound zinc levels during healing.
Impact of pharmaceutical dosage forms on the pharmacokinetics of roxithromycin in healthy human volunteers.
OBJECTIVES: The impact of two different pharmaceutical preparations on the pharmacokinetics of roxithromycin was investigated in healthy human volunteers. METHODS: The degradation kinetics and products of roxithromycin were investigated in simulated gastric fluid and simulated intestinal fluid. Two oral dosage forms of roxithromycin were employed: enteric-coated pellets and dispersible tablets. RESULTS: The degradation half-time of roxithromycin in simulated gastric fluid was 0.23 h, and three main degradation products were characterized. In contrast, roxithromycin was stable in simulated intestinal fluid and remained unchanged after a 1.00 h incubation. The roxithromycin enteric-coated pellets exhibited higher bioavailability and a more potent serum antibacterial activity than the dispersible tablets. CONCLUSIONS: The type of oral dosage forms of roxithromycin altered its pharmacokinetics. Whether or not this affects the in vivo antibacterial efficacy requires further study.
Determination of the structure of a synthetic impurity in guaifenesin: modification of a high-performance liquid chromatographic method for phenylephrine hydrochloride, phenylpropanolamine hydrochloride, guaifenesin, and sodium benzoate in dosage forms.
An impurity present in all commercial guaifenesin-containing dosage forms examined was isolated and identified as 2-(2-methoxyphenoxy) 1,3-propanediol (VI). The eluant of a previously developed stability-indicating liquid chromatographic method for phenylephrine hydrochloride (I), phenylpropanolamine hydrochloride (II), and guaifenesin (III) was modified to yield a better separation between phenylpropanolamine and the impurity. The method was expanded to include sodium benzoate (IV), a preservative found in some liquid formulations.
Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
Impurity profiling of dicloxacillin sodium bulk drug and pharmaceutical dosage forms subjected to stability studies is evaluated. Of many impurities detected in HPLC analysis, three were not reported in the literature. The impurities have been identified by LC-MS; isolated by preparative HPLC; and characterised by NMR, Mass spectroscopy and IR. Pure impurities obtained by isolation were co-injected with dicloxacillin sodium sample to confirm the retention times in HPLC. Structure elucidation of these degradation products by spectral data has been discussed in detail.
Determination of content uniformity and distribution characteristics of an investigational drug in its tablets dosage form and granule by ICP-AES.
An investigational drug (A) in its calcium salt form has been developed as the tablet dosage form. Monitoring drug distribution and uniformity in granules and tablets during early stage formulation/process development is critical for drug product quality control and process robustness. In this report, an efficient and reliable analytical method for monitoring drug compound A uniformity and distribution has been developed by analyzing calcium, the counter ion of the drug substance, by Inductively Coupled Plasma Atomic Emission Spectrometer (ICP-AES). In this method, calcium in compound A granule and tablet samples was digested with 1 M hydrochloric acid by heating at 90 degrees C for 2 h. The resulting suspension was centrifuged, and the supernatant was directly aspirated into an ICP-AES. This method has been validated to demonstrate satisfactory precision, accuracy, specificity and sensitivity. Finally, this method has been used to analyze sieve fraction granules and tablets of drug compound A. The data generated were highly comparable to those by validated HPLC methods (UV method can not be applicable due to significant bias). In comparison with HPLC methods, this method demonstrates a significantly improved efficiency with very short analysis time (1 min per sample), and can be used as an excellent alternative for UV and HPLC methods to support formulation screening.
The use of surface analysis techniques to determine the route of manufacture of tablet dosage forms.
Analytical methods for determining the manufacturing process of tablet dosage forms have not been previously reported. The use of surface analysis techniques in particular X-ray Photoelectron Spectroscopy and Time of Flight Secondary Ionization Mass Spectrometry will be described and a model proposed which allows the prediction of the route of manufacture in calcium phosphate and cellulosic-based tablet formulations. Results of the application of this model to evaluate prototype tablet formulations prepared by wet granulation or direct compression will be reported. Strengths and limitations of the model will be discussed.